MedTrace Logo

Radiation Plus Cetuximab in Locally Advanced Non-Small Cell Lung Cancer (NSCLC)

NCT00115518 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2011-08-05

No results posted yet for this study

Summary

The purpose of this trial is to study combined locoregional radiotherapy with cetuximab in non-operable NSCLC Stage III (Phase II trial).

Endpoints:

safety and feasibility (primary) response, survival, time to progression (secondary)

Conditions

  • Carcinoma, Non-Small-Cell Lung

Interventions

DRUG

cetuximab

After Cetuximab loading dose. weekly cetuximab during RT. 13 weeks cetuximab weekly maintenance

Sponsors & Collaborators

  • Heidelberg University

    lead OTHER

Principal Investigators

  • Klaus K Herfarth, MD · Heidelberg University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-05-31
Primary Completion
2009-06-30
Completion
2010-08-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00115518 on ClinicalTrials.gov